TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma

References

• Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. Lyon: International Agency for Research on Cancer; 2017.
   Google Scholar
• Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110(4):1398–1403.
   PubMed Web of Science ®Google Scholar
• Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481–494.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Smith MR, Siddiqi T, et al. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017;58(7):1607–1616.
   PubMed Web of Science ®Google Scholar
• Carreras J, Kikuti YY, Bea S, et al. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). Histopathology. 2017;70(4):595–621.
   PubMed Web of Science ®Google Scholar
• Tsuyama N, Sakata S, Baba S, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130(4):489–500.
   PubMed Web of Science ®Google Scholar
• Gaudio F, Tamma R, Ingravallo G, et al. Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. Ann Hematol. 2018;97(4):663–668.
   PubMed Web of Science ®Google Scholar
• Steele KE, Tan TH, Korn R, et al. Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis. J Immunother Cancer. 2018;6(1):20.
   PubMedGoogle Scholar
• Hupp M, Williams S, Dunnette B, et al. Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas. Hum Pathol. 2019;83:124–132.
   PubMed Web of Science ®Google Scholar
• Zhong W, Xu X, Zhu Z, et al. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients. Oncotarget. 2017;8(30):49757–49772.
   PubMedGoogle Scholar
• Deng Y, Chen X, Huang C, et al. EZH2/Bcl-2 coexpression predicts worse survival in diffuse large B-cell lymphomas and demonstrates poor efficacy to rituximab in localized lesions. J Cancer. 2019;10(9):2006–2017.
   PubMed Web of Science ®Google Scholar
• Neves Filho EHC, Hirth CG, Frederico IAS, et al. EZH2 expression is dependent on myc and TP53 regulation in diffuse large B-cell lymphoma. APMIS. 2020;128(4):308–315.
   PubMed Web of Science ®Google Scholar
• Bram Ednersson S, Stenson M, Stern M, et al. Ednersson S, Stenson M, Stern M, et al Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients. Br J Haematol. 2018;181(6):770–781.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–3459.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122(7):1256–1265.
   PubMed Web of Science ®Google Scholar
• Arthur SE, Jiang A, Grande BM, et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018;9(1):4001.
   PubMedGoogle Scholar
• Lunning MA, Green MR. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J. 2015;5:e361.
   PubMed Web of Science ®Google Scholar
• Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 1996;384(6610):641–643.
   PubMed Web of Science ®Google Scholar
• Ogryzko VV, Schiltz RL, Russanova V, et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87(5):953–959.
   PubMed Web of Science ®Google Scholar
• Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32(4):606–613.
   PubMed Web of Science ®Google Scholar
• Ci W, Polo JM, Cerchietti L, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009;113(22):5536–5548.
   PubMed Web of Science ®Google Scholar
• Yang Y, Shaffer AL 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723–737.
   PubMed Web of Science ®Google Scholar
• Cho EC, Mitton B, Sakamoto KM. CREB and leukemogenesis. Crit Rev Oncog. 2011;16(1–2):37–46.
   PubMedGoogle Scholar
• Gao B, Xu W, Zhong L, et al. p300, but not PCAF, collaborates with IRF-1 in stimulating TRIM22 expression independently of its histone acetyltransferase activity. Eur J Immunol. 2013;43(8):2174–2184.
   PubMed Web of Science ®Google Scholar
• Lee MS, Kim JH, Lee JS, et al. Prognostic significance of CREB-binding protein and CD81 expression in primary high grade non-muscle invasive bladder cancer: identification of novel biomarkers for bladder cancer using antibody microarray. PLoS One. 2015;10(4):e0125405.
   PubMed Web of Science ®Google Scholar
• Gao C, Zhang RD, Liu SG, et al. Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia. Eur J Haematol. 2017;99(2):150–159.
   PubMed Web of Science ®Google Scholar
• Li JY, Daniels G, Wang J, et al. TBL1XR1 in physiological and pathological states. Am J Clin Exp Urol. 2015;3(1):13–23.
   PubMed Web of Science ®Google Scholar
• Jung H, Yoo HY, Lee SH, et al. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP. Oncotarget. 2017;8(10):17038–17049.
   PubMedGoogle Scholar
• Ma M, Yu N. Over-expression of TBL1XR1 indicates poor prognosis of serous epithelial ovarian cancer. Tohoku J Exp Med. 2017;241(3):239–247.
   PubMed Web of Science ®Google Scholar
• Liu F, He Y, Cao Q, et al. TBL1XR1 is highly expressed in gastric cancer and predicts poor prognosis. Dis Mark. 2016;2016:1–7.
   Web of Science ®Google Scholar
• Wang J, Ou J, Guo Y, et al. TBLR1 is a novel prognostic marker and promotes epithelial–mesenchymal transition in cervical cancer. Br J Cancer. 2014;111(1):112–124.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhan Y, Li X, et al. Nuclear TBLR1 as an ER corepressor promotes cell proliferation, migration and invasion in breast and ovarian cancer. Am J Cancer Res. 2016;6(10):2351–2360.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–1874.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159–166.
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181–185.
   PubMed Web of Science ®Google Scholar
• Rizzardi AE, Johnson AT, Vogel RI, et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol. 2012;7(1):42.
   PubMedGoogle Scholar